MX2016002289A - Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de las tos aguda, sub-aguda o cronica. - Google Patents
Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de las tos aguda, sub-aguda o cronica.Info
- Publication number
- MX2016002289A MX2016002289A MX2016002289A MX2016002289A MX2016002289A MX 2016002289 A MX2016002289 A MX 2016002289A MX 2016002289 A MX2016002289 A MX 2016002289A MX 2016002289 A MX2016002289 A MX 2016002289A MX 2016002289 A MX2016002289 A MX 2016002289A
- Authority
- MX
- Mexico
- Prior art keywords
- acute
- treatment
- diaminopyrimidine
- sub
- chronic cough
- Prior art date
Links
- 206010011224 Cough Diseases 0.000 title abstract 4
- 208000013116 chronic cough Diseases 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100040479 P2X purinoceptor 2 Human genes 0.000 abstract 1
- 101710189968 P2X purinoceptor 2 Proteins 0.000 abstract 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract 1
- 102000002294 Purinergic P2X Receptors Human genes 0.000 abstract 1
- 108010000836 Purinergic P2X Receptors Proteins 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- -1 diaminopyrimidine compound Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención pertenece a compuestos de diaminopirimidina que tienen actividad como antagonistas de receptores purinérgicos de P2X, y a métodos para el tratamiento de enfermedades asociadas con receptores de P2X que comprenden administrar una cantidad efectiva de un compuesto de diaminopirimidina. Más particularmente, los métodos se proporcionan para utilizar antagonistas de P2X3 y/o P2X2/3 en el tratamiento de la tos, tos crónica, una necesidad para toser durante padecimientos y trastornos respiratorios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869174P | 2013-08-23 | 2013-08-23 | |
PCT/US2014/052389 WO2015027212A1 (en) | 2013-08-23 | 2014-08-22 | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016002289A true MX2016002289A (es) | 2016-09-06 |
MX367657B MX367657B (es) | 2019-08-30 |
Family
ID=52480919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016002289A MX367657B (es) | 2013-08-23 | 2014-08-22 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
Country Status (21)
Country | Link |
---|---|
US (3) | US9284279B2 (es) |
EP (2) | EP3035932A4 (es) |
JP (3) | JP6546592B2 (es) |
KR (1) | KR102196885B1 (es) |
CN (1) | CN105682659B (es) |
AU (1) | AU2014308606B2 (es) |
CA (1) | CA2921395C (es) |
CL (3) | CL2016000400A1 (es) |
CR (1) | CR20160093A (es) |
HK (1) | HK1222126A1 (es) |
IL (1) | IL244131B (es) |
MX (1) | MX367657B (es) |
MY (1) | MY195728A (es) |
NI (1) | NI201600029A (es) |
NZ (1) | NZ716977A (es) |
PE (1) | PE20160431A1 (es) |
PH (1) | PH12016500357A1 (es) |
RU (1) | RU2650118C2 (es) |
SG (1) | SG11201601145RA (es) |
UA (1) | UA118851C2 (es) |
WO (1) | WO2015027212A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY195728A (en) | 2013-08-23 | 2023-02-07 | Afferent Pharmaceuticals Inc | Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough |
ES2792682T3 (es) | 2014-02-10 | 2020-11-11 | Respivant Sciences Gmbh | Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos |
PT3104853T (pt) | 2014-02-10 | 2020-01-14 | Respivant Sciences Gmbh | Tratamento com estabilizadores de mastócitos para distúrbios sistémicos |
WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
JP6877441B2 (ja) * | 2015-09-29 | 2021-05-26 | アファレント ファーマシューティカルズ インコーポレイテッド | 咳の処置における使用のためのジアミノピリミジンp2x3及びp2x2/3受容体修飾因子 |
US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
US10662162B2 (en) * | 2016-03-25 | 2020-05-26 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
CN109803724A (zh) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | 用于治疗肺纤维化的色甘酸组合物 |
US10988460B2 (en) | 2016-12-15 | 2021-04-27 | Afferent Pharmaceuticals, Inc. | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore |
BR112019012340B1 (pt) * | 2016-12-20 | 2022-01-11 | Afferent Pharmaceuticals, Inc. | Forma a de citrato cristalino de 5-(2,4-diamino-pirimidin-5-iloxi)-4-isopropil-2-metoxibenzenossulfonamida, bem como sua composição farmacêutica e usos |
US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
IL277024B (en) | 2018-03-15 | 2022-09-01 | Danmir Therapeutics Llc | ", 5"-dimethoxybenzoyl-3'-amino-3'-deoxyadenosine-5'-triphosphates and their pharmaceutical uses |
KR20210005592A (ko) * | 2018-04-23 | 2021-01-14 | 머크 샤프 앤드 돔 코포레이션 | 페녹시 디아미노피리미딘 화합물의 신규 합성 방법 |
CA3100099A1 (en) * | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
EP3826635A4 (en) * | 2018-07-23 | 2022-04-27 | Trevi Therapeutics, Inc. | TREATMENT OF CHRONIC COUGH, DIFFICULT BREATHING AND DYSPNEA |
CN113559104A (zh) * | 2018-10-05 | 2021-10-29 | 盐野义制药株式会社 | 慢性咳嗽治疗用药物 |
US20220211703A1 (en) * | 2019-04-30 | 2022-07-07 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
WO2020221276A1 (zh) * | 2019-04-30 | 2020-11-05 | 北京泰德制药股份有限公司 | 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途 |
BR112022004398A2 (pt) | 2019-09-19 | 2022-05-31 | Shionogi & Co | Cristal de derivado de 1,3,5-triazina ou solvato do mesmo e método para produção do mesmo |
CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1725540T5 (da) * | 2004-03-05 | 2012-10-22 | Hoffmann La Roche | Diaminopyrimidiner som p2x3- og p2x2/3-antagonister |
US20060029548A1 (en) * | 2004-07-22 | 2006-02-09 | Amir Pelleg | Methods of diagnosing, monitoring and treating pulmonary diseases |
EP1924566B1 (en) | 2005-09-01 | 2016-01-13 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
CA2619919C (en) * | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
SI1924264T1 (sl) * | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
EP1926716B1 (en) * | 2005-09-01 | 2011-10-19 | F. Hoffmann-La Roche AG | Process for synthesis of aryloxy diaminopyrimidines |
AU2007304280B2 (en) | 2006-10-04 | 2013-01-31 | F. Hoffmann-La Roche Ag | Process for synthesis of phenoxy diaminopyrimidine derivatives |
WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
US9550763B2 (en) * | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
MY195728A (en) | 2013-08-23 | 2023-02-07 | Afferent Pharmaceuticals Inc | Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough |
US9133647B2 (en) * | 2013-10-11 | 2015-09-15 | Nexkey, Inc. | NFC or BLE based contactless lock with charge monitoring of its energy storage |
-
2014
- 2014-08-22 MY MYPI2016000327A patent/MY195728A/en unknown
- 2014-08-22 JP JP2016536497A patent/JP6546592B2/ja active Active
- 2014-08-22 PE PE2016000285A patent/PE20160431A1/es unknown
- 2014-08-22 RU RU2016105581A patent/RU2650118C2/ru active
- 2014-08-22 CN CN201480058491.3A patent/CN105682659B/zh active Active
- 2014-08-22 CA CA2921395A patent/CA2921395C/en active Active
- 2014-08-22 WO PCT/US2014/052389 patent/WO2015027212A1/en active Application Filing
- 2014-08-22 EP EP14838254.2A patent/EP3035932A4/en not_active Withdrawn
- 2014-08-22 UA UAA201601740A patent/UA118851C2/uk unknown
- 2014-08-22 US US14/466,713 patent/US9284279B2/en active Active
- 2014-08-22 EP EP21159088.0A patent/EP3865134A1/en active Pending
- 2014-08-22 NZ NZ716977A patent/NZ716977A/en unknown
- 2014-08-22 AU AU2014308606A patent/AU2014308606B2/en active Active
- 2014-08-22 SG SG11201601145RA patent/SG11201601145RA/en unknown
- 2014-08-22 KR KR1020167007167A patent/KR102196885B1/ko active IP Right Grant
- 2014-08-22 MX MX2016002289A patent/MX367657B/es active IP Right Grant
- 2014-08-22 CR CR20160093A patent/CR20160093A/es unknown
-
2016
- 2016-02-02 US US15/013,798 patent/US9724346B2/en active Active
- 2016-02-15 IL IL244131A patent/IL244131B/en active IP Right Grant
- 2016-02-22 NI NI201600029A patent/NI201600029A/es unknown
- 2016-02-22 CL CL2016000400A patent/CL2016000400A1/es unknown
- 2016-02-23 PH PH12016500357A patent/PH12016500357A1/en unknown
- 2016-08-31 HK HK16110333.7A patent/HK1222126A1/zh unknown
-
2017
- 2017-08-01 US US15/665,595 patent/US10206922B2/en active Active
-
2018
- 2018-08-08 CL CL2018002137A patent/CL2018002137A1/es unknown
- 2018-08-08 CL CL2018002138A patent/CL2018002138A1/es unknown
-
2019
- 2019-03-25 JP JP2019055849A patent/JP7210348B2/ja active Active
-
2022
- 2022-10-18 JP JP2022166618A patent/JP7423725B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500357A1 (en) | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough | |
PH12019501448A1 (en) | Immunomodulator compounds and methods of use | |
MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
MX2016005560A (es) | Compuestos agonistas triples de glucagon-glp-1-gip. | |
MX2021011939A (es) | Compuestos neuroactivos y metodos de uso de los mismos. | |
BR112014020826A2 (pt) | moduladores e métodos de uso | |
BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
MX2015010749A (es) | Anticuerpos humanos para nav1.7. | |
MY189912A (en) | Substituted xanthines and methods of use thereof | |
MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
PH12017500710A1 (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
MX2016006657A (es) | Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. | |
MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
IT201600130012A1 (it) | Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale | |
BR112016019893A2 (pt) | composições de glicoproteína sialilada e seus usos | |
PH12015502820A1 (en) | Nanoparticulate formulation comprising a trpa1 antagonist | |
NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
EA201491522A1 (ru) | Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина | |
ES2586805T3 (es) | Análogos de péptidos para tratar enfermedades y trastornos | |
JO3621B1 (ar) | مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll | |
ITRM20130717A1 (it) | Securfunds h2020 - applicativo informatico per la gestione e la rendicontazione dei progetti dell'unione europea del programma h2020 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |